MiniMed 670G System Improves Glycemic Outcomes in Children With T1D

Share this content:
The MiniMed 670G system automates and personalizes the delivery of basal insulin. <i>Photo courtesy of Medtronic.</i>
The MiniMed 670G system automates and personalizes the delivery of basal insulin. Photo courtesy of Medtronic.

Similar to findings in adolescents and adults, the MiniMedTM 670G insulin pump system (Medtronic, Northridge, California) improves glycemic outcomes in children with type 1 diabetes, according to an abstract presented at ENDO 2018: The Endocrine Society Annual Meeting, held March 17-20 in Chicago, Illinois.1

Michael Wood, MD, associate professor of pediatrics and clinical director of the Pediatric Diabetes Program at the University of Michigan Medical School in Ann Arbor, and colleagues compared data from the hybrid-closed loop (HCL) pivotal trial in type 1 diabetes (ClinicalTrials.gov Identifier: NCT02463097) involving 30 adolescents (14-21 years of age) and 94 adults (22-75 years of age) with data from 105 children (7-13 years of age) from 9 sites.

Like the pivotal trial, the HCL system was used in open-loop mode for a 2-week run-in period followed by a 3-month in-home study period with the HCL auto mode enabled. Glycated hemoglobin (HbA1c) and percentage of time spent in the target glucose range (70-180 mg/dL) for the run-in and study periods were compared between children, adolescents, and adults.

HbA1c decreased from 7.9±0.8% to 7.5±0.6%, 7.7±0.8% to 7.1±0.6%, and 7.3±0.9% to 6.8±0.6%, in children, adolescents, and adults, respectively (P <.001 for all). The percentage of time spent in the target glucose range increased from 56.2±11.4% to 65.0±7.7%, 60.4±10.9% to 67.2±8.2%, and 68.8±11.9% to 73.8±8.4%, respectively (P <.001 for all).

There were no episodes of severe hypoglycemia or diabetic ketoacidosis, and no serious device-related adverse events in children.  All except 3 children continued to use the pump after the study concluded.

“The MiniMed 670G system can effectively manage diabetes and lead to improved time in the target glucose range and [HbA1c] for individuals with type 1 diabetes between the ages of 7 and 75 who require at least eight units of insulin daily,” said Dr Wood in a press release.2 “The pilot studies of the system were encouraging, but it was necessary to test it in a larger, more diverse population to confirm its effectiveness.”

Disclosure: This study was funded by Medtronic.


Visit Endocrinology Advisor's conference section for more highlights from ENDO 2018.

References

  1. Wood MA, Shulman DI, Pinhas-Hamiel O, et al. Results of MiniMed™ 670G System in-home use: glycemic outcomes of children, adolescents, and adults. Presented at: ENDO 2018: The Endocrine Society Annual Meeting; Chicago, IL; March 17-20, 2018. Abstract SAT-179.
  2. An insulin pump known to be effective in adolescents and adults also benefits children [press release]. Washington, CD: Endocrine Society. Published March 17, 2018. Accessed March 17, 2018.
You must be a registered member of Endocrinology Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-Newsletters